Medexus Pharmaceuticals Inc. (MEDXF)

2.1200 +0.1488 (+7.55%) At close: 03:18PM EST

Medexus Pharmaceuticals Inc.

35 Nixon Road
Unit 1
Bolton, ON L7E 1K1
Canada

https://www.medexus.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Kenneth d'Entremont	CEO & Director	688.3k	N/A	N/A
Mr. Bill Poncy	Sr. VP of Commercial Operations - United States	439.69k	N/A	N/A
Mr. Michael David Adelman	Gen. Mang., U.S. Operations	576.85k	N/A	1971
Mr. Marcel Konrad	Chief Financial Officer	N/A	N/A	1976
Ms. Tina Byers CFA	Exec. of Investor Relations	N/A	N/A	N/A
Mr. Ian C. Wildgoose Brown	Gen. Counsel & Corp. Sec.	N/A	N/A	N/A
Mr. Brian Peters	VP of Sales & Marketing - United States	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis psoriasis, and juvenile idiopathic arthritis; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also include Treosulfan, a conditioning agent used prior to stem cell transplantation; and Triamcinolone Hexacetonide for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Bolton, Canada.

Corporate governance

Medexus Pharmaceuticals Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.